The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Q&A With Thierry Gillebert From Ghent University: New Studies Look at Ways to Improve Cardiac Care
On a daily basis cardiologists face patients with a wide variety of conditions. A review of recent studies show just how far the treatment of many of these conditions have come.
Procedure Does Not Reduce Stroke Risk in Patients with Atrial Fibrillation
Left atrial appendage obliteration reduces stroke risk in patients with nonvalvular atrial fibrillation, but a new study suggests that the procedure does not reduce stroke risk in atrial fibrillation patients after bioprosthetic mitral valve replacement.
Promising Results on Gene Therapy for Congestive Heart Failure
California researchers report good results in a phase II study of a gene therapy for congestive heart failure. The news comes five months after Celladon's Mydicar gene therapy for CHF failed to meet its trial's endpoints.
FDA Approves First 24-Hour Extended-Release Aspirin
September 9th 2015Cardiovascular patients are the focus of the recent drug approval by the Food and Drug Administration (FDA). Branded under the name Durlaza, the 24-hour extended-release aspirin is the first of its kind and is expected to become available before the end of the year.
Heart Failure, Diabetes, and Medication: An Interesting Triad
September 9th 2015A study published in Metabolic Syndrome and Related Disorders indicates that sodium glucose cotransporter-2 inhibitors (SGLT2 inhibitors, which affect both supply and demand pathways in the heart) may be the preferred treatment for diabetics with heart failure.
If a patient requires bypass surgery one of the factors doctors will look at when considering the operation is the person's blood pressure. A recent study looked at whether it could be safe to operate when the patient's pressure is higher or lower than previously accepted.
Pacemakers and AICDs Interrogation Reports and Interpretation of EKGs
September 9th 2015A general practitioner can gain a better understanding of a patient’s underlying cardiac ailments by focusing on the fundamentals of pacemakers and automated implantable cardioverter defibrillators (AICDs).In the first part of this 3-part article (“Pacemakers and AICDs: The ABCs”), we discussed distinguishing between pacemakers and AICDs. The second part (“Pacemakers and AICDs: Nomenclature and Malfunction”) addressed pacemaker nomenclature and device function, malfunction, and pseudomalfunction. Here we cover interrogation reports and interpretation of EKGs.
When a patient checks into the emergency room, whether on their own or in an ambulance, time is of the essence to make the correct diagnosis. As technology improves so does the ability to make diagnoses in medicine that much faster. This way doctors can treat the patients that need the help the most while the others can be safely discharged and sent home.
While digoxin has been a popular medication in the past, particularly for patients with atrial fibrillation, a recent study looked at whether the medication was indeed beneficial for treatment when compared to placebo or no pharmaceutical therapy at all. Digoxin may be a popular treatment for some patients, but often doctors cannot look at just one condition when treating and have to consider multiple factors and issues.
Q&A With Kay-Tee Khaw From University of Cambridge: Finding New Results Through Population Medicine
Treating one patient for an illness can answer some questions for doctors. However, in many cases looking at the larger patient population can answer not only why the patients got sick, but what can be done to keep them healthy in the long run.
As technology improves telemedicine is becoming a more viable option to treat a wide variety of conditions. While the idea of telemedicine can be easily implemented into practice there are still concerns that need to be addressed for the field to progress. These issues can include liability and governance over doctors and where their patients are located.
Binge-Watching Television Spikes Blood Clot Risk
Couch potatoes, beware. According to a recent study presented at the European Society of Cardiology 2015 Congress (ESC) in London, UK, watching television for longer than five hours each day doubles the likelihood of suffering a fatal pulmonary embolism.
Wire-Free Pacemaker Shows Promise
New York City-based researchers reported that a leadless cardiac pacemaker (Nanostim/St. Jude Medical) implanted non-surgically via a catheter through the femoral vein had a better safety record than conventional devices. But it has other limitations.
Atrial Fibrillation: Rivaroxaban Helps Prevent Stroke and Major Bleeding
September 1st 2015The first real-world study of its kind revealed that rivaroxaban, marketed as Xarelto, can reduce the risk of stroke and major bleeding in patients with atrial fibrillation (AF) – a group that is five times more likely to suffer a stroke compared to the general population.
Heart Failure Patients: Gene Transfer Therapy Does Not Help
Barry Greenberg, MD, UCSD Sulpizio Cardiovascular Center, La Jolla, California, USA, presented results from the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b (CUPID 2) gene transfer study at the European Society of Cardiology 2015 Congress.
PCSK9 Inhibitor Dramatically Reduces Cholesterol in Patients with Familial Hypercholesterolemia
The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)- approved in July in the US - lowered cholesterol in patients with familial hypercholesterolemia to levels "unreachable with statins" researchers said at the European Society of Cardiology meeting in London, UK.
In the time since Florence Nightingale first developed the profession of nursing as it is known today a lot has changed for the men and women in the field. Even still the work they do has been a key part of the medical world as training has increased and improved as well.